摘要
评价新一代氟喹诺酮类药司帕沙星对耐多药肺结核病(MDRTB)的治疗作用。将80例MDRTB患者随机平分两组:治疗组用司帕沙星0.1gqn;对照组用氧氟沙星0.2gtid,疗程均为6个月,同时辅以其他抗痨药物。有效率治疗组(85%)优于对照组(80%),痰菌阴转率(77.5%)优于对照组(70%),耐药率(5%)优于对照组(17.5%),两组相比无显著性差异(P>0.05),说明司帕沙星对MDRTB有一定治疗价值。
To study the therapeutic efficacy of new generation fluoroquinolones drug Sparfloxacin (Shi Bao Fu made in Shan Xi Da Tong Tian Feng Pharmaceutical Company) in treating MDR TB. Eighty patients with MDR TB were randomly divided into two groups. One group ( n =40) was treated with sparflxoacin, 0.1g , qn. The other group ( n =40) was treated with ofloxacin, 0.2g, tid. The course of treatment of each group lasted six months, and also with the other anti tubercoulosis drugs in the same time. The effective rates were 85% in sparfloxacin group, and 80% in ofloxacin group. The sputum M.tuberculosis clearance rates were 77.5% in sparfloxacin group,and 70% in ofloxacin group. The resistant drug rates were 5% in sparfloxacin group, and 17.5% in ofloxacin group, P >0.05. It was concluded that sparfloxacin is an effective drug in the treatment of MDR TB.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2000年第1期53-55,共3页
Chinese Journal of Antibiotics
关键词
司帕沙星
氧氟沙星
肺结核
多药耐药性
Sparfloxacin
Ofloxacin
Multiple drug resistant pulmonary tuberculosis (MDR TB)
Clincal efficacy
